Peter Neubeck
Chairman at Emergence Therapeutics AG
Profile
Peter Neubeck is currently the Co-Chairman Supervisory Board at Emergence Therapeutics AG, the Director at TACALYX GmbH, the Director at Synendos Therapeutics AG, a Venture Partner at TVM Capital GmbH (since 2010), a Partner at Kurma Partners SA, and a Partner at Kurma Partners (since 2019).
He previously worked as the Director & Chief Business Officer at Aspireo Pharmaceuticals Ltd.
Dr. Neubeck holds an MBA from INSEAD, and doctorate degrees from Ludwig-Maximilians-Universität München and Harvard Medical School.
Peter Neubeck active positions
Companies | Position | Start |
---|---|---|
TVM Capital GmbH
TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Private Equity Investor | 16/07/2009 |
Kurma Partners /DE/ | Private Equity Investor | 31/12/2018 |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Director/Board Member | - |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Chairman | - |
Synendos Therapeutics AG
Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | Director/Board Member | - |
Kurma Partners SA
Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Private Equity Investor | - |
Former positions of Peter Neubeck
Companies | Position | End |
---|---|---|
Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Director/Board Member | - |
Training of Peter Neubeck
INSEAD | Masters Business Admin |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Harvard Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 7 |
---|---|
TVM Capital GmbH
TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Finance |
Kurma Partners SA
Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Finance |
Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Health Technology |
Kurma Partners /DE/ | Finance |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Commercial Services |
Synendos Therapeutics AG
Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | Health Technology |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Health Technology |
- Stock Market
- Insiders
- Peter Neubeck